Palliative radiotherapy for gross hematuria in patients with advanced cancer

Abstract This study assessed the efficacy of palliative radiotherapy for gross hematuria caused by advanced cancer. Patients who received palliative radiotherapy to control gross hematuria in two hospitals between October 2006 and May 2020 were retrospectively reviewed. We evaluated the gross hematu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mami Ogita, Jiro Kawamori, Hideomi Yamashita, Keiichi Nakagawa
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b25f8b21a5f74835a6c2d4cf8b171515
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b25f8b21a5f74835a6c2d4cf8b171515
record_format	dspace
spelling	oai:doaj.org-article:b25f8b21a5f74835a6c2d4cf8b1715152021-12-02T14:49:34ZPalliative radiotherapy for gross hematuria in patients with advanced cancer10.1038/s41598-021-88952-82045-2322https://doaj.org/article/b25f8b21a5f74835a6c2d4cf8b1715152021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88952-8https://doaj.org/toc/2045-2322Abstract This study assessed the efficacy of palliative radiotherapy for gross hematuria caused by advanced cancer. Patients who received palliative radiotherapy to control gross hematuria in two hospitals between October 2006 and May 2020 were retrospectively reviewed. We evaluated the gross hematuria response, gross hematuria control duration, blood transfusion rate, blood transfusion-free duration, and overall survival. Cox multivariate analysis was performed to examine factors associated with hematuria control duration. Fifty-three consecutive patients were included. The most frequently used dose fractionation regimen was 30 Gy in 10 fractions (BED10 = 39 Gy), followed by 20 Gy in 5 fractions (BED10 = 20 Gy). Forty patients (76%) became gross hematuria free. The median hematuria control duration was 4.3 months (95% confidence interval 1.9–6.6). Twenty-six patients received blood transfusion 3 months before radiotherapy; 17 of them (65%) were free from blood transfusion 1 month after radiotherapy. A high BED10 (≥ 36 Gy) was a statistically significant factor for hematuria control duration in the multivariate analysis (P = 0.02). Palliative radiotherapy can effectively relieve gross hematuria irrespective of the primary tumor site. A high BED10 may be recommended for a prolonged hematuria control duration if patients have a good prognosis.Mami OgitaJiro KawamoriHideomi YamashitaKeiichi NakagawaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mami Ogita Jiro Kawamori Hideomi Yamashita Keiichi Nakagawa Palliative radiotherapy for gross hematuria in patients with advanced cancer
description	Abstract This study assessed the efficacy of palliative radiotherapy for gross hematuria caused by advanced cancer. Patients who received palliative radiotherapy to control gross hematuria in two hospitals between October 2006 and May 2020 were retrospectively reviewed. We evaluated the gross hematuria response, gross hematuria control duration, blood transfusion rate, blood transfusion-free duration, and overall survival. Cox multivariate analysis was performed to examine factors associated with hematuria control duration. Fifty-three consecutive patients were included. The most frequently used dose fractionation regimen was 30 Gy in 10 fractions (BED10 = 39 Gy), followed by 20 Gy in 5 fractions (BED10 = 20 Gy). Forty patients (76%) became gross hematuria free. The median hematuria control duration was 4.3 months (95% confidence interval 1.9–6.6). Twenty-six patients received blood transfusion 3 months before radiotherapy; 17 of them (65%) were free from blood transfusion 1 month after radiotherapy. A high BED10 (≥ 36 Gy) was a statistically significant factor for hematuria control duration in the multivariate analysis (P = 0.02). Palliative radiotherapy can effectively relieve gross hematuria irrespective of the primary tumor site. A high BED10 may be recommended for a prolonged hematuria control duration if patients have a good prognosis.
format	article
author	Mami Ogita Jiro Kawamori Hideomi Yamashita Keiichi Nakagawa
author_facet	Mami Ogita Jiro Kawamori Hideomi Yamashita Keiichi Nakagawa
author_sort	Mami Ogita
title	Palliative radiotherapy for gross hematuria in patients with advanced cancer
title_short	Palliative radiotherapy for gross hematuria in patients with advanced cancer
title_full	Palliative radiotherapy for gross hematuria in patients with advanced cancer
title_fullStr	Palliative radiotherapy for gross hematuria in patients with advanced cancer
title_full_unstemmed	Palliative radiotherapy for gross hematuria in patients with advanced cancer
title_sort	palliative radiotherapy for gross hematuria in patients with advanced cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/b25f8b21a5f74835a6c2d4cf8b171515
work_keys_str_mv	AT mamiogita palliativeradiotherapyforgrosshematuriainpatientswithadvancedcancer AT jirokawamori palliativeradiotherapyforgrosshematuriainpatientswithadvancedcancer AT hideomiyamashita palliativeradiotherapyforgrosshematuriainpatientswithadvancedcancer AT keiichinakagawa palliativeradiotherapyforgrosshematuriainpatientswithadvancedcancer
_version_	1718389468237398016

Palliative radiotherapy for gross hematuria in patients with advanced cancer

Ejemplares similares